Boston Oncology maintains a diversified portfolio of generic and biosimilar therapeutics—USFDA / EMA registered and licensed from world-renowned innovator companies—supporting the entire patient journey.
High-impact biologic therapies selected where localization can broaden access, stabilize supply, and improve the economics of treatment at system scale.
Hulio | 40 mg/0.8 mL | Solution for injection in a pre-filled syringe
Hulio | 40 mg/0.8 mL | Solution for injection in a pre-filled pen
Yesafili | 40 mg/mL | Solution for injection
Enoxaparin BOS | 20 mg/0.2 mL, 40 mg/0.4 mL, 60 mg/0.6 mL, 80 mg/0.8 mL | Solution for injection
Nepexto | 50 mg/mL | Solution for injection in a pre-filled pen
Nepexto | 25 mg/0.5 mL, 50 mg/mL | Solution for injection in a pre-filled syringe
Evonanz | 6 mg/mL | Solution for injection
Zelyssa | 6 mg/mL | Solution for injection
Tyenne | 80 mg/4 mL, 200 mg/10 mL, 400 mg/20 mL | Solution for infusion
Tyenne | 162 mg/0.9 mL | Solution for injection in a pre-filled syringe
Tyenne | 162 mg/0.9 mL | Solution for injection in a pre-filled pen
Yesintek | 130 mg | Concentrate for solution for infusion
Yesintek | 45 mg | Solution for injection
Yesintek | 45 mg, 90mg | Solution for injection in a pre-filled syringe
A broad portfolio designed to support continuity across complex treatment pathways—not merely filling isolated product slots.
Birato | 250 mg | Tablet
Acalabrutinib BOS | 100 mg | Capsule, Hard
Bortezomib BOS | 3.5 mg | Powder for solution for injection
Busulfan BOS | 60 mg/10 mL | Concentrate for solution for infusion
Xatiza | 60 mg/1.5 mL | Concentrate and solvent for solution for infusion
Cabozantinib BOS | 20 mg, 40 mg, 60 mg | Film-coated tablet
Emcap | 500 mg | Tablet
Carfilzombin BOS | 10 mg, 30 mg, 60 mg | Powder for solution for injection or infusion
Tykodas | 50 mg, 70 mg, 100 mg | Film-coated tablet
Docetaxel BOS | 20 mg/2 mL, 80 mg/8 mL | Concentrate for solution for infusion
Eribulin BOS | 1 mg | Solution for injection
Everolimus BOS | 5 mg, 10 mg | Tablet
Gemcitabine BOS | 1000 mg/30 mL | Concentrate for solution for infusion
Tecana | 100 mg/5 mL | Concentrate for solution
Lenalidomide BOS | 5 mg, 10 mg, 15 mg, 25 mg | Capsule
Lenvatinib BOS | 4 mg, 10 mg | Capsule
Xorola | 2.5 mg | Film-coated tablet
Nintib | 100 mg, 150 mg | Capsule
Olaparib BOS | 100 mg, 150 mg | Film-coated tablet
Pemitax | 500 mg | Powder solution for injection
Pomalidomide BOS | 1 mg, 2 mg, 3 mg, 4 mg | Capsule
Sirolimus BOS | 1 mg, 2 mg | Film-coated tablet
Sorafenib BOS | 200 mg | Film-coated tablet
Apeto | 15 mg, 100 mg | Powder for solution for injection
Sermitor | 60 mg | Tablet
Trumavar | 15 mg/6.14 mg, 20 mg/8.19 mg | Film-coated tablet
Complex formulations and targeted therapies addressing consequential gaps beyond high-volume commodity generics.
Apixaban BOS | 2.5 mg, 5 mg | Film-coated tablet
Bibecfo | 100 μg | Pressurised inhalation, solution
Bimatoprost BOS | 0.01% | Eye drops, solution
Ovolv | 0.25 mg | Powder and solvent for solution for injection
Chlorothiazide BOS | 500 mg | Powder for solution for injection
Cidofovir BOS | 75 mg | Concentrate for solution for infusion
Ferasiro | 90 mg, 180 mg, 360 mg | Film-coated tablet
Varenya | 50 mg, 100 mg | Extended-release tablet
Eltrombopag BOS | 25 mg, 50 mg | Film-coated tablet
Ruhava | 3 mg, 4 mg, 5 mg | Film-coated tablet
Ibrutinib BOS | 140 mg, 280 mg, 420 mg, 560 mg | Film-coated tablet
Idelalisib BOS | 100 mg, 150 mg | Film-coated tablet
Levetiracetam BOS | 500 mg/5 mL | Solution for injection
Methotrexate BOS | 2.5 mg | Tablet
Octreotide BOS | 100 μg/mL | Concentrate for solution for injection
Sekpal | 75 mg, 100 mg, 125 mg | Capsule
Hemabo | 24 mg/1.2 mL | Solution for injection
Fenido | 267 mg, 801 mg | Film-coated tablet
Ossentiv | 24 mg, 49 mg, 97 mg | Film-coated tablet
Tasylev | 1.34 mg/mL | Solution for injection in a pre-filled pen
Teriflunomide BOS | 14 mg | Film-coated tablet
Tedbosis | 1 mg | Powder for concentrate for solution for infusion
Acidoxax | 4 mg | Concentrate for solution for infusion
Essential, time-sensitive medicines selected for hospital environments where reliable availability is inseparable from care.
Cisatracurium BOS | 2 mg/mL | Solution for injection/infusion
Demexa | 200 mcg/mL | Solution for injection/infusion
Fomepizole BOS | 1.5 g/1.5 mL | Solution for injection/infusion
Ketorolac BOS | 30 mg/mL | Solution for injection
Milrinone BOS | 10 mg/10 mL | Solution for injection
Rocuronium Bromide BOS | 50 mg/5 mL | Solution for injection
Tranexamic Acid BOS | 1000 mg/10 mL | Solution for injection
Vasopressin BOS | 20 U/mL | Solution for infusion
Hospital-focused therapies addressing serious infections and difficult-to-source needs, with local supply reducing vulnerability to disruption.
Anidulafungin BOS | 100 mg | Powder for concentrate for solution for infusion
Azithromycin BOS | 500 mg | Powder for solution for injection
Copsfin | 50 mg, 70 mg | Powder for concentrate for solution for infusion
Daptomycin BOS | 350 mg | Powder for solution for injection or infusion
Foscarnet BOS | 6000 mg/250 mL | Solution for infusion
Oselow | 75 mg | Capsule
Tigecycline BOS | 50 mg | Powder for infusion
Voriole | 200 mg | Powder for solution
Medicines should be used only as directed by a qualified healthcare professional. Product availability, approved indications, and regulatory status may vary by market.
For questions about a medicine, speak with your physician or pharmacist. To report a suspected adverse event, medication error, lack of effectiveness, or product-quality concern, use Boston Oncology Arabia’s pharmacovigilance reporting service.
